Release details

2016-01-28 19:59 CET
  • Print
  • Share Share
en

CORRECTION: MPI is issued patent in Australia

This is a correction of the announcement from 07:51 28.01.2016 CET. Reason for the correction: Wrong date
Hoersholm; January 28, 2016 - Medical Prognosis Institute A/S (MPI.CO) (Denmark and Phoenix, AZ, USA) announced today IP Australia has issued a Notice of Acceptance for a patent of MPI's microRNA profiles to predict response to 70 different cancer treatments. Three months after the publication of the Notice of Acceptance, the patent will issue.

 
"After obtaining a patent in the USA on our mRNA based drug response technology, this is an important expansion of MPI's patent portfolio, geographically as well as topically," said Peter Buhl Jensen, CEO.
 

About MPI's multiple biomarker called Drug Response Predictor - DRP(TM)
MPI's lead product, the DRP(TM) diagnostic platform, is a tool to develop tumor-derived gene signatures that may predict which cancer patients are highly likely responders to a given anticancer product. The DRP(TM) has been tested in 32 trials, where 26 trials showed that drug-specific DRP(TM) Biomarkers could predict which patients had a positive effect of the treatment. The DRP(TM) platform has also been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center. The DRP(TM) method can be used to design the Clinical Development Plan, i.e. to select which indications are relevant for a given anticancer drug.  Further to and in addition to this, individual patients' gene patterns can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of those patients who have a high likelihood of response to the drug. The DRP(TM) platform can be used in all cancer types and has been patented for more than 60 anticancer drugs in the US.

About MPI
Medical Prognosis Institute advances personalized medicine by partnering with cancer drug developers to apply its DRP(TM) diagnostic platform to streamline and de-risk clinical trials and drug development via biomarker optimization, patient stratification, and development of companion diagnostics.

For further information, please contact

MPI
Peter Buhl Jensen, CEO
e-mail: pbj@medical-prognosis.com
Phone: +45 21 60 89 22

Certified Advisor: Carsten Yde Hemme, PricewaterhouseCoopers, Strandvejen 44, 2900 Hellerup, Denmark

HUG#1982148